Abstract
Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Current Proteomics
Title: How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?
Volume: 1 Issue: 1
Author(s): Scott D. Patterson
Affiliation:
Keywords: parallel protein analysis, mass spectrometry, proteome, proteomics
Abstract: Despite the recent advances in parallel protein-based analyses the proportion of the protein composition of any specific tissue or organism that is currently being analyzed is still unknown. The ultimate aim of proteomics is to characterize all of the proteins in a biological system under study, but much has been gained from knowledge of smaller subsets of the proteome. Therefore, while techniques and instrumentation are being improved to increase the sensitivity of analysis, it is just as important to answer the question of what depth of analysis is required for reasonable conclusions to be reached. The questions to be answered and the resulting depth of analysis required will vary depending upon whether the understanding is required for diagnostic markers, therapeutic targets or biological systems. The issues associated with increasing the depth of analysis of proteins in the context of these areas will be discussed. However, it should be noted that merely increasing the amount of data acquired will not necessarily increase the amount of knowledge of a particular system and as such careful implementation of proteomic methods is required to advance these fields of research.
Export Options
About this article
Cite this article as:
Patterson D. Scott, How Much of the Proteome Do We See with Discovery-Based Proteomics Methods and How Much Do We Need to See?, Current Proteomics 2004; 1 (1) . https://dx.doi.org/10.2174/1570164043488306
DOI https://dx.doi.org/10.2174/1570164043488306 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intraoperative Targeted Optical Imaging: A Guide towards Tumor-Free Margins in Cancer Surgery
Current Pharmaceutical Biotechnology Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design How Do Microtubule-Targeted Drugs Work? An Overview
Current Cancer Drug Targets Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Fertility Preservation in Women After the Cancer
Current Pharmaceutical Design Sulfation of Drug Compounds by the Zebrafish Cytosolic Sulfotransferases (SULTs)
Drug Metabolism Letters Inducers of Heme Oxygenase-1
Current Pharmaceutical Design Etoposide, Topoisomerase II and Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Modeling Anti-HIV Compounds: The Role of Analogue-Based Approaches
Current Computer-Aided Drug Design Kefir: A Synbiotic with Approved Anticarcinogenic Properties
Current Bioactive Compounds Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Patent Selections
Recent Patents on Biotechnology Dihydroresveratrol Type Dihydrostilbenoids: Chemical Diversity, Chemosystematics, and Bioactivity
Current Medicinal Chemistry Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Chemokine Receptor-directed Agents as Novel Anti-HIV-1 Therapies
Current Topics in Medicinal Chemistry